In the past decade, the incorporation of ICIs, targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4), program cell death 1 (PD-1), and PD-L1 have significantly advanced the treatment paradigm in NSCLC. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.